Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01006707 · ClinicalTrials.gov registry record · NA

Functional Magnetic Resonance Imaging of Opioid Withdrawal in Healthy Human Volunteers

A NA study of Substance-Related Disorders, sponsored by Stanford University.

Completed
Registry status
NA
Development phase
15
Enrollment target
1
Study location

NCT01006707 is a NA study of Substance-Related Disorders that has completed, run by Stanford University. The registered enrollment target is 15 participants, below the 1,521-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01006707, a NA study of Substance-Related Disorders, has completed, sponsored by Stanford University.

COMPLETED
Registry status
NA
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

Opioid medications are commonly used for pain relief. When given over time, physical dependence can occur. This results in unpleasant side effects--such as agitation and nausea--if opioid medications are suddenly stopped. However, we do not know how withdrawal affects the brain. We know that a medication named Ondansetron can help ease or prevent symptoms associated with opioid withdrawal. Through imaging of the brain by fMRI, we hope to see how opioid withdrawal, with and without the administration of ondansetron, affects brain activity.

Interventions

  • DRUG Ondansetron

Study Locations (1)

California

  • Stanford University School of Medicine - Stanford

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2010-11
Est. Completion 2013-07
Phase NA

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT01006707

The ClinicalTrials.gov registry entry for NCT01006707 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,521-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (99% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Substance-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Ondansetron is the first listed.

NCT01006707 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT01006707 about?

NCT01006707 is a clinical study titled "Functional Magnetic Resonance Imaging of Opioid Withdrawal in Healthy Human Volunteers". Opioid medications are commonly used for pain relief. When given over time, physical dependence can occur. This results in unpleasant side effects--such as agitation and nausea--if opioid medications are suddenly stopped. However, we do not know how withdrawal affects the brain. We know that a medic...

What is the current status of trial NCT01006707?

This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2010-11. Estimated completion is 2013-07.

What conditions does trial NCT01006707 study?

This clinical trial studies the following conditions: Substance-Related Disorders.

What interventions are being tested in trial NCT01006707?

The interventions under investigation include: Ondansetron (DRUG).

Who is sponsoring clinical trial NCT01006707?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01006707 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Substance-Related Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.